- Works count
- 583
- Citation count
- 47,419
- H-index
- 109
- i10-index
- 314
Research interests
Publications
Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests
Nature Medicine · 2024 · 10.1038/s41591-024-02869-z
Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets
Nature Immunology · 2023 · https://doi.org/10.1038/s41590-023-01588-w
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
Nature Medicine · 2022 · 10.1038/s41591-022-02074-w
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study
The Lancet Neurology · 2021 · https://doi.org/10.1016/s1474-4422(21)00214-3
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
Brain · 2021 · https://doi.org/10.1093/brain/awab223
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
Alzheimer s & Dementia · 2021 · https://doi.org/10.1002/alz.12283
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease
JAMA Neurology · 2021 · https://doi.org/10.1001/jamaneurol.2021.1858
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures
Nature Medicine · 2021 · https://doi.org/10.1038/s41591-021-01348-z
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
Nature Communications · 2020 · 10.1038/s41467-020-15436-0
Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
JAMA · 2020 · https://doi.org/10.1001/jama.2020.12134
Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
Nature Medicine · 2020 · https://doi.org/10.1038/s41591-020-0755-1
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts
The Lancet Neurology · 2020 · https://doi.org/10.1016/s1474-4422(20)30071-5
Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status
JAMA Neurology · 2019 · 10.1001/jamaneurol.2019.1632
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology
JAMA Neurology · 2019 · https://doi.org/10.1001/jamaneurol.2019.1534
Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease
JAMA Neurology · 2019 · 10.1001/jamaneurol.2019.0765
Discriminative Accuracy of [ 18 F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders
JAMA · 2018 · https://doi.org/10.1001/jama.2018.12917
Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia
Annals of Neurology · 2018 · https://doi.org/10.1002/ana.25333
Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity
Nature Communications · 2017 · https://doi.org/10.1038/s41467-017-01150-x
Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
JAMA Neurology · 2017 · 10.1001/jamaneurol.2016.6117
Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia
JAMA Psychiatry · 2017 · https://doi.org/10.1001/jamapsychiatry.2017.3391
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
The Lancet Neurology · 2017 · https://doi.org/10.1016/s1474-4422(17)30159-x
CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
Annals of Clinical and Translational Neurology · 2016 · 10.1002/acn3.274
Plasma tau in Alzheimer disease
Neurology · 2016 · https://doi.org/10.1212/wnl.0000000000003246
Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression
JAMA Neurology · 2015 · 10.1001/jamaneurol.2015.3037
Amyloid biomarkers in Alzheimer's disease
Trends in Pharmacological Sciences · 2015 · 10.1016/j.tips.2015.03.002
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia
JAMA · 2015 · https://doi.org/10.1001/jama.2015.4668
Smoking and increased Alzheimer's disease risk: A review of potential mechanisms
Alzheimer s & Dementia · 2014 · 10.1016/j.jalz.2014.04.009
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
Alzheimer s & Dementia · 2011 · 10.1016/j.jalz.2011.05.2243
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
JAMA · 2009 · https://doi.org/10.1001/jama.2009.1064
Current projects
No projects listed.